Clinical Trial Update: Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates a four-drug regimen (lenalidomide, ixazomib, dexamethasone, and daratumumab) in transplant-ineligible patients with newly diagnosed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• DEXAMETHASONE (Dexamethasone)
• NINLARO (ixazomib)
• Revlimid (lenalidomide)

Snippet

Sponsor: Alliance Foundation Trials, LLC. | Conditions: Myeloma, Multiple | Phase 2 | Status: ACTIVE_NOT_RECRUITING